Research programme: TT 223 + CD26 antigen antagonists - Transition Therapeutics

Drug Profile

Research programme: TT 223 + CD26 antigen antagonists - Transition Therapeutics

Alternative Names: G1 + CD26 antigen antagonists; TT 223 + CD26 antigen antagonists; TT-223 + DPP-IV inhibitors

Latest Information Update: 20 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transition Therapeutics
  • Class Antihyperglycaemics; Carrier proteins; CD antigens; Gastrointestinal hormones; Hormones; Neuropeptides; Peptide hormones
  • Mechanism of Action CD26 antigen inhibitors; Gastrin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diabetes mellitus

Most Recent Events

  • 20 May 2008 Discontinued - Preclinical for Diabetes mellitus in Canada (Injection/PO combination)
  • 14 Mar 2008 Transition Therapeutics and Eli Lilly enter into a licensing and collaboration agreement for gastrin-based therapies in Diabetes
  • 06 Jul 2007 Preclinical trials in Diabetes mellitus in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top